2393 Stock Overview
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Tianjin Lisheng Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.34 |
| 52 Week High | CN¥28.80 |
| 52 Week Low | CN¥17.66 |
| Beta | 0.23 |
| 1 Month Change | -1.46% |
| 3 Month Change | 3.40% |
| 1 Year Change | 6.29% |
| 3 Year Change | 26.70% |
| 5 Year Change | -5.51% |
| Change since IPO | -58.25% |
Recent News & Updates
Shareholder Returns
| 2393 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.2% | 3.0% | 1.6% |
| 1Y | 6.3% | -12.9% | -15.1% |
Return vs Industry: 002393 exceeded the CN Pharmaceuticals industry which returned -12.9% over the past year.
Return vs Market: 002393 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 2393 volatility | |
|---|---|
| 2393 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 002393 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002393's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 1,328 | Fujun Wang | www.lishengpharma.com |
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers its products in various forms comprising tablets, soft and hard capsules, granules, dripping pills, freeze-dried powder injections, and water injections for use in various therapeutic fields, such as circulatory system, systemic anti-infection, digestive system, nervous and endocrine system, respiratory system, musculoskeletal, and genitourinary system, as well as antitumor and immune system modulation, and big health series products.
Tianjin Lisheng Pharmaceutical Co.,Ltd. Fundamentals Summary
| 2393 fundamental statistics | |
|---|---|
| Market cap | CN¥4.48b |
| Earnings (TTM) | CN¥361.83m |
| Revenue (TTM) | CN¥1.15b |
12.4x
P/E Ratio3.9x
P/S RatioIs 2393 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2393 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.15b |
| Cost of Revenue | CN¥487.97m |
| Gross Profit | CN¥665.06m |
| Other Expenses | CN¥303.24m |
| Earnings | CN¥361.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 1.96 |
| Gross Margin | 57.68% |
| Net Profit Margin | 31.38% |
| Debt/Equity Ratio | 0.6% |
How did 2393 perform over the long term?
See historical performance and comparison